[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"preterm-labor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:preterm-labor":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,40,71,108,150,177,201,231,259,287],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100618788","uterine-artery-doppler-indices-and-uterocervical-angle-measurment-in-prediction-of-preterm-labor-100618788",false,"NCT07336173","Uterine Artery Doppler Indices and Uterocervical Angle Measurment in Prediction of Preterm Labor","Role of Uterine Artery Doppler Indices and Sonographic Measurement of Uterocervical Angle in Predicting Preterm Labor","Inclusion Criteria:\n\n1. Patient who will give verbal \\& written will informed consent.\n2. Pregnant women between 18 and 40 years old of age\n3. Singleton pregnancy\n4. Gestational age will be confirmed by first trimester ultrasound scan (\\\u003C14 weeks).\n5. Gestational age between 24 and 34 weeks .\n6. Threatened preterm labor which is defined as:\n\nPresence of at least one uterine contraction every 10 minutes lasting ≥30 seconds . Cervical dilatation ≤3 cm . Cervical effacement \\\u003C80%.\n\nExclusion Criteria:\n\nObstetric:\n\n1. Ruptured membranes\n2. Clinical evidence of Chorioamnionitis.\n3. Fetal compromise on evaluation.\n4. Severe obstetric complications (e.g., severe Preeclampsia, Eclampsia).\n5. Diagnosed intrauterine growth restriction (IUGR).\n6. Congenital fetal anomalies.\n7. Multiple pregnancies.\n8. Prior cervical surgery (e.g., cone biopsy, cerclage).\n\nNon-Obstetric:\n\n1. Significant maternal medical disorders (e.g., chronic hypertension, diabetes mellitus, liver dysfunction).\n2. Severe non-obstetric complications (e.g., acute abdomen).",true,"FEMALE","18 Years","40 Years",{"count":21,"type":22},47,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate the role of uterine artery doppler indices and uterocervical angle measurement in prediction of preterm labor .The main question it aims to answer is:\n\nDoes combination of both uterine artery doppler indices and uterocervical angle measurement increase sensitivity and specificity for prediction of established preterm labor ? Participants already performing uterine artery doppler as part of their regular antenatal care .measurement of anterior uterocervical angle will be added between 24 to 34 weeks gestation to predict preterm labor in candidates .",[26],"Preterm Labor","RECRUITING","2026-05-14",{"date":30,"type":31},"2026-05-18","ACTUAL",{"date":33,"type":31},"2026-01-15",{"date":35,"type":22},"2026-08",{"name":37,"class":38},"Kafrelsheikh University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":39},"100616431","the-combined-effect-of-magnesium-palmitoylethanolamide-high-molecular-weight-hyaluronic-acid-vitamin-b6-and-vitamin-d-in-preventing-preterm-birth-100616431","NCT07305519","The Combined Effect of Magnesium, Palmitoylethanolamide, High-Molecular-weight Hyaluronic Acid, Vitamin B6, and Vitamin D in Preventing Preterm Birth:","The Combined Effect of Magnesium, Palmitoylethanolamide, High-Molecular-weight Hyaluronic Acid, Vitamin B6, and Vitamin D in Preventing Preterm Birth: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Signed informed consent\n\nSingleton pregnancy\n\nMaternal age ≥ 18 years\n\nGestational age between 20+0 and 34+0 weeks at enrollment\n\nCervical length between 15 mm and 30 mm measured by transvaginal ultrasound\n\nExclusion Criteria:\n\n* Fetal structural anomalies\n\nMaternal chronic diseases or pregnancy-related conditions, including diabetes, hypertension, preeclampsia, cardiovascular disease, infections, or autoimmune disorders\n\nMultiple gestation\n\nFetal growth abnormalities (estimated fetal weight \\\u003C10th or \\>90th percentile)\n\nPrelabor rupture of membranes (PROM)",{"count":48,"type":22},150,"INTERVENTIONAL",[51],"NA","The aim of the study is to assess the effect of a combination of Magnesium, Palmitoylethanolamide, high-molecular-weight Hyaluronic Acid, Vitamin B6, and Vitamin D in women at risk of preterm birth (PTB).",[26],[55,56,57,58,59,60,61],"preterm labor","preterm birth","prematurity","magnesium","hyaluronic acid","vitamin B6","Vitamin D","2026-04-28",{"date":64,"type":31},"2026-04-29",{"date":66,"type":31},"2026-04-01",{"date":68,"type":22},"2028-01-01",{"name":70,"class":38},"University of Roma La Sapienza",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":79,"conditions":80,"keywords":87,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100594112","the-combined-first-trimester-screening-100594112","NCT07015203","The Combined First Trimester Screening","Inclusion Criteria:\n\n* A woman over 18 years old in the first trimester of pregnancy (11th-13th gestational week)\n* Signed the Consent to Participate in the Project and GDPR.\n\nExclusion Criteria:\n\n* Unsigned the Consent to Participate in the Project and the Consent to the Processing of Personal Data.",{"count":78,"type":22},2000,"The project is a national, prospective, multicenter pilot project. The project is focus on setting up the combined first trimester screening in the Czech Republic.\n\nThe combined first trimester screening is aimed at predicting and detecting the most serious obstetric complications, such as the great obstetrical syndromes (preeclampsia, fetal growth restriction, preterm labor and intrauterine fetal demise \"IUFD\") and structural congenital defects (morphological and chromosomal).\n\nThe primary objective of the project is to create a unified methodology for performing and evaluating the combined first trimester screening in connection with the National Health Information System (hereinafter referred to as \"NHIS\"), which will enable recording, providing analysis and linking recorded clinical parameters with data in the NHIS. The pilot project will also provide data for modeling appropriate mechanisms for reimbursement from public health insurance.",[81,82,83,26,84,85,86],"Preeclampsia (PE)","Fetal Growth Restriction","Congenital Abnormalities","Intrauterine Fetal Demise","Genetics Syndrome","Pregnancy Overdue - Week 41+6",[88,89,90,91,92,93,94,95,96],"preeclampsia","prediction","prevention","maternal risk factors","Mean Arterial Pressure","Uterine artery Pulsatility Index","Placental Growth Factor","acetylsalicylic acid","Czech Republic","2026-04-16",{"date":99,"type":31},"2026-04-17",{"date":101,"type":31},"2025-06-15",{"date":103,"type":22},"2027-04-30",{"name":105,"class":106},"Institute of Health Information and Statistics of the Czech Republic","OTHER_GOV",3,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":118,"conditions":119,"keywords":134,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100613200","prior-study-pre-eclampsia-risk-in-oocyte-recipients-100613200","NCT07263490","PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)","PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients) - Investigating Matching, Biomarkers and Outcomes.","PRIOR","Inclusion Criteria:\n\n* Age \\> 18 years\n* BMI \\\u003C 35 kg\u002Fm2\n* Normal wet smear within the past three years\n* Both nulli- and multiparous\n* Singletons and multiple gestations\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* BMI \\> 35 kg\u002Fm2\n* HIV\u002F hepatitis\n* Essential hypertension\n* Chronic kidney disease\n* Undiagnosed vaginal bleeding\n* Uterine malformations\n* Persisting ovarian cysts\n* Tumors in hypothalamus, pituitary, thyroid, or adrenal glands.\n* Previous breast cancer\n* Known BRCA 1 or 2 gene\n* Unregulated thyroid disease\n* Cardiovascular disease\n* Breast feeding\n* Present or previous chemotherapy\u002Fradiation therapy\n* Present or previous malignant disease\n* Smoking\n* Alcohol\u002Fdrug abuse",{"count":117,"type":22},462,"The aim of this prospective observational cohort study is to investigate the pathophysiological mechanisms behind and risk of pre-eclampsia in women pregnant after fertility treatment with oocyte donation. The participants are included in of of two cohorts. One includes women pregnant after oocyte donation whereas the other includes women pregnant after IVF treatment with autologous oocytes.\n\nParticipants will be followed throughout pregnancy with blood samples, blood pressure, clinical controls and ultrasound examinations. Clinical outcomes will be registered post-partum.",[120,121,122,123,124,125,126,127,128,129,130,26,131,132,133],"Pre-eclampsia","Oocyte Donation","Pre-Eclampsia; Complicating Pregnancy","Pre-Eclampsia; Mild","Pre-Eclampsia, Severe","Pre-eclampsia or Eclampsia With Pre-existing Hypertension","ART","Neonatal Morbidity","Neonatal Mortality","Placental Abruption","Gestational Diabetes","Post-partum Hemorrhage (PPH)","Intrauterine Growth Restriction (IUGR)","Hypertensive Disorders of Pregnancy",[120,135,126,136,137,138,139],"Preeclampsia","Gestational hypertension","Oocyte donation","Egg donation","Gamete donation","2026-04-07",{"date":142,"type":31},"2026-04-13",{"date":144,"type":31},"2024-10-21",{"date":146,"type":22},"2028-06-01",{"name":148,"class":38},"Copenhagen University Hospital, Hvidovre",6,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":16,"sex":17,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":162,"studyType":23,"phases":4,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":39},"100196134","prospective-data-bank-creation-to-study-vaginal-conditions-100196134","NCT01829204","Prospective Data Bank Creation to Study Vaginal Conditions","A Prospective Longitudinal Data Bank Creation to Study Vaginal Conditions With a Novel Diagnostic Approach","CRIPB-13-002","Inclusion Criteria:\n\n* All patients willing to participate, and give informed consent, and\n* Asymptomatic, non-pregnant, healthy women ages 21 to 75 years with no previous history of any chronic or recurrent vulvovaginal condition who attend our clinical offices for their annual well-woman physical examination.\n* Non-pregnant women ages 21 to 75 years being evaluated for any gynecological vulvovaginal condition.\n* Pregnant women ages 21 to 75 years who are both asymptomatic and healthy\n* Pregnant women ages 21 to 75 who have any gynecological vulvovaginal condition\n\nExclusion Criteria:\n\n* Asymptomatic patients ages \\\u003C 21 or \\> 75, or symptomatic patients ages \\\u003C 21 or \\> 75 years.\n* Patients diagnosed with cancer or having any medical condition that is not under control including: diabetes mellitus, hypertension, collagen disease, hemoglobinopathy, renal insufficiency, depression, anxiety, psychosis and panic attacks\n* Patients unable to follow the protocol or unwilling to participate","21 Years","75 Years",{"count":161,"type":22},550,"12 Months","The purpose of this study is to identify and elucidate the pattern and perhaps role of atypical proteins, cytokines and vaginal microbial flora in the pathogenic mechanisms involved in the development of vulvodynia, recurrent fungal and bacterial vaginosis and preterm labor.",[165,166,167,26],"Vulvodynia","Mycoses","Bacterial Vaginosis","2025-12-10",{"date":170,"type":31},"2025-12-18",{"date":172,"type":4},"2013-04",{"date":174,"type":22},"2027-12",{"name":176,"class":38},"Texas Tech University Health Sciences Center",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":49,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":199,"locationsCount":39},"100484307","development-and-clinical-evaluation-of-an-innovative-medical-device-to-predict-preterm-birth-predimap-100484307","NCT05586334","Development and Clinical Evaluation of an Innovative Medical Device to Predict Preterm Birth (PrediMAP)","Development and Clinical Evaluation of an Innovative Medical Device to Predict Preterm Birth: From Basic Research to Obstetric Emergencies","PrediMAP","Inclusion Criteria:\n\n* Pregnant with live fetus(es)\n* Emergency room visit between 22 and 34 days of pregnancy + 6 days\n* For a suspicion of PTL defined by :\n\n  * Uterine contractions (UC) objectified during the consultation (questioning, clinical examination, external tocography),\n  * And\u002For clinical or ultrasound changes of the uterine cervix;\n* OR for any other reason but with EC and\u002For clinical or ultrasound changes of the cervix on clinical examination\n* Social security coverage or AME: patients receiving AME are at higher risk of PAD and preterm delivery.\n* Signature of consent\n\nExclusion Criteria\n\n* Age \\\u003C 18 years;\n* Premature rupture of membranes\n* Patient in labor with imminent delivery.\n* Total absence of social care\n* Minor or protected adult (guardianship or curatorship)\n* Persons who do not speak French and not accompanied by a French-speaking third party\n* Multiple pregnancy \\>= 3",{"count":186,"type":22},3600,[51],"The purpose of this study is to clinically validate the predictive performance (sensitivity and specificity) of the PrediMAP in-vitro diagnostic medical device to predict delivery within 7 days in the target population of women consulting obstetric emergencies for preterm labor (PTL).",[26],[191,192,55,56,89],"obstetrics","medical device","2025-11-17",{"date":195,"type":31},"2025-11-20",{"date":197,"type":31},"2023-06-08",{"date":174,"type":22},{"name":200,"class":38},"Assistance Publique - Hôpitaux de Paris",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":49,"phases":211,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":39},"100425559","maternal-stress-on-human-milk-and-infant-outcomes-100425559","NCT04821544","Maternal Stress on Human Milk and Infant Outcomes","Effects of Maternal Stress on Human Milk Composition and Subsequent Infant Outcomes","Inclusion Criteria:\n\n* Mothers of newborn infants at Kootenai Health NICU and the Palouse region\n\nExclusion Criteria:\n\n\\-","50 Years",{"count":210,"type":22},500,[51],"The overarching purpose of this study is to determine if a modified 8-week mindfulness-based intervention (with a focus on self-compassion; MBSC) or 8 weeks of 2000 IU vitamin D supplementation will reduce stress and increase self-compassion in mothers of preterm infants and beneficially modify the human milk produced, and subsequently improve infant health.",[214,26],"Postpartum Depression",[216,217,218,219,220,221],"Maternal stress","Mindfulness","Human milk bioactives","Infant metabolome","Maternal transcriptome","Infant transcriptome","2025-05-16",{"date":224,"type":31},"2025-05-18",{"date":226,"type":31},"2021-05-01",{"date":228,"type":22},"2027-06-30",{"name":230,"class":38},"University of Idaho",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":16,"sex":238,"minAge":239,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":49,"phases":243,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":249,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":39},"100561375","effects-of-kangaroo-care-on-circadian-rhythm-growth-and-physiological-effects-100561375","NCT06589349","Effects of Kangaroo Care on Circadian Rhythm, Growth and Physiological Effects","Effects of Kangaroo Care on Circadian Rhythm, Growth and Physiological Effects of Newborns Effect of Parameters on Breast Milk Cortisol Levels: Randomized Controlled Study","Inclusion Criteria:\n\n* Being between 28+0-37 weeks of pregnancy,\n* Birth weight \\>1000 g,\n* APGAR score \\>7 at the 5th minute after birth,\n* Ability to feed every 2-3 hours\n\nExclusion Criteria:\n\n* Getting mechanical ventilation support\n* Undergoing surgery\n* Having diseases and disorders such as congenital brain malformations, meningitis, seizures, encephalopathy, congenital abnormalities, history of intraventricular bleeding, herpes, sepsis and heart or metabolic diseases.\n* Taking medication that affects sleep patterns, such as theophylline, phenobarbital, midazolam, caffeine, fentalnil\n* Having developed intraventricular hemorrhage","ALL","28 Weeks","37 Weeks",{"count":242,"type":22},56,[51],"This study was planned to investigate the effect of premature babies receiving regular kangaroo care in the NICU on circadian rhythm, growth and physiological parameters, and breast milk cortisol levels",[246,247,26,248],"Newborn; Vitality","Sleep","Care Pattern, Maternal","NOT_YET_RECRUITING","2024-09-05",{"date":252,"type":31},"2024-09-19",{"date":254,"type":22},"2024-09-15",{"date":256,"type":22},"2025-04-15",{"name":258,"class":38},"Sibel Küçükoğlu",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":238,"minAge":18,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":49,"phases":270,"briefSummary":271,"conditions":272,"keywords":274,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":284,"locationsCount":286},"100492962","low-dose-antenatal-corticosteroids-for-late-preterm-delivery-100492962","NCT05698966","Low Dose Antenatal Corticosteroids for Late Preterm Delivery","Low Dose Antenatal Corticosteroids for Late Preterm Delivery (LoDAC Study)","LoDAC","Inclusion Criteria:- - Singleton pregnancy at 34 weeks 0 days to 36 weeks 5 days of gestation at risk for \u002F high probability of delivery in the late preterm period (34+0-36+5 weeks of gestation).\n\nCriteria for determination of late preterm delivery risk:\n\n1. Preterm uterine contractions with intact membranes, and at least 3 cm dilation or 75% cervical effacement\n2. Spontaneous rupture of the membranes\n3. Expected preterm delivery for any other indication via induction or cesarean between 24 hours to 7 days after the planned randomization, as determined by the obstetric provider.\n\n   \\-\n\n   Exclusion Criteria: They had already received a full course of betamethasone.\n   * Expected delivery in less than 12 hours, irrespective of cause including: 1)ruptured membranes in the presence of more than 6 contractions per hour or cervical dilation of 3 centimeters or more unless oxytocin was withheld for at least 12 hours (although other induction agents were allowed), 2) chorioamnionitis, 3) cervical dilation of 8 cm or more, and 4) evidence of non-reassuring fetal status requiring immediate delivery.\n   * Prior ACS treatment\n   * Current known or suspected infection ( viral, bacterial or other)\n   * Pre-gestational diabetes mellitus.\n   * Any infection that required antibiotics or hospitalization in the month prior to study allocation - Poor understanding of the inform consent language","45 Years",{"count":269,"type":22},1510,[51],"This is a study proposal for a clinical trial to evaluate the effectiveness of a reduced dose of antenatal betamethasone (a steroid medication) in preventing respiratory problems in late preterm infants (born between 34 and 36 weeks of gestation). The study will be conducted in medical centers in Israel and will involve women who are at high risk for delivering a late preterm infant. The participants will be randomly assigned to receive either a full dose (12 mg) or a quarter dose (3 mg) of betamethasone, administered 24 hours apart. The main outcome measure of the study will be the incidence of respiratory problems or neonatal death within 72 hours of delivery in the two groups. The study is designed to determine if the reduced dose of betamethasone is non-inferior (i.e., not significantly worse) than the full dose in preventing respiratory problems in late preterm infants.",[273,26],"Respiratory Morbidity",[275,276,277],"corticosteroids","low dose","late prerterm","2024-04-09",{"date":280,"type":31},"2024-04-10",{"date":282,"type":31},"2022-01-01",{"date":68,"type":22},{"name":285,"class":38},"Rambam Health Care Campus",16,{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":49,"phases":296,"briefSummary":298,"conditions":299,"keywords":305,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":39},"100366175","phase-4-latency-antibiotics-in-previable-pprom-18-07--22-67-wga-100366175","NCT04047849","Latency Antibiotics in Previable PPROM, 18 0\u002F7- 22 6\u002F7 WGA","The Effect of Antibiotics on Latency in Previable Prelabor Rupture of Membranes Between 18 0\u002F7 and 22 6\u002F7 Weeks Gestational Age","Inclusion Criteria:\n\n1. Singleton gestation\n2. Gestational age of greater than 18 0\u002F7 but less than or equal to 22 6\u002F7\n3. Diagnosis of prelabor premature rupture of membranes as determined by clinical examination noting either\u002For 1) visualization of amniotic fluid passing from the cervical canal and pooling in the vagina via sterile speculum examination, 2) a basic pH (i.e., positive nitrazine) test of vaginal fluid, 3) arborization (ferning) of dried vaginal fluid identified via microscopic examination, or 4) an amniotic fluid index (AFI) of less than 4cm\n4. Greater than or equal to 18 years of age\n5. Those with no known drug allergies or significant adverse reactions to azithromycin or amoxicillin\n6. Afebrile at the time of presentation and throughout 24-hour observation period\n7. Patient must be able to provide informed consent\n\nExclusion Criteria:\n\n1. Fetal anomalies in current pregnancy\n2. Diabetes mellitus, including both pre-gestational and gestational\n3. Abnormal placentation\n4. Poor dating with dating ultrasound performed later than or equal to 20 0\u002F7 weeks\n5. Current subchorionic hemorrhage or current vaginal bleeding on presentation\n6. Hypertensive disease, including pre-gestational chronic hypertension, gestational hypertension and pre-eclampsia\u002Feclampsia\n7. History of amniocentesis during this pregnancy\n8. History of cervical incompetence, history of cerclage in previous pregnancy or current cerclage in place\n9. Current documented urinary tract infection or bacteriuria\n10. Current documented genital tract infection (Chlamydia, gonorrhea, or trichomonas)\n11. Immunocompromised (i.e., HIV positive, daily steroid use, or a history of autoimmune disease for which the patient is currently undergoing treatment with immunotherapy medication)",{"count":295,"type":22},34,[297],"PHASE4","This study is a non-blinded, prospective, randomized controlled trial designed to compare the effect of outpatient oral antibiotics (i.e., amoxicillin and azithromycin) on the length of time (days) that pregnancy continues after a patient's water bag has ruptured prematurely. If a patient has been diagnosed with rupture of their water bag between 18 0\u002F7 weeks and 22 6\u002F7 weeks and there are no other associated complications with the pregnancy, the patient is eligible for initial consideration for this study. Patients will be admitted to the hospital for a 24-hour monitoring period. If the patient remains without further complications during this monitoring period, the patient will be eligible for enrollment. If enrollment is desired, the patient will be randomly assigned to receive either antibiotics (treatment arm of the study) or no antibiotics (control arm of the study). The treatment arm will receive an outpatient, 7-day course of oral antibiotics (azithromycin and amoxicillin) with the first dose given in the hospital to ensure no side effects. The control arm will not receive outpatient antibiotics. Both groups will have weekly, office follow-up visits with high-risk pregnancy specialists to ensure no further complications. Both groups will be admitted to the hospital if the patients reach 23 0\u002F7 weeks without complications. At this time the patients will receive all medications and therapies recommended by the governing board of OBGYNs. Subjects of both groups will also be admitted before 23 0\u002F7 weeks if further complications noted either at their clinic follow up visits or anytime outside of the hospital. The duration of time that the patient remains pregnant after breaking of the water bag will be compared in each group. The investigators will also see if there is a difference in the number of patients able to reach 23 0\u002F7 weeks between each group (treatment versus control).",[300,301,302,303,304,26],"Rupture of Membranes; Delayed Delivery (Following Spontaneous Rupture)","Rupture of Membranes; Premature","Rupture of Membranes; Premature, Affecting Fetus","Preterm Birth","Preterm PROM (Pregnancy)",[306,307,308,309,310,311],"Previable","PPROM","Premature prelabor rupture of membranes","Preterm","Preterm birth","Latency antibiotics","2021-01-07",{"date":314,"type":31},"2021-01-11",{"date":316,"type":31},"2019-08-28",{"date":318,"type":22},"2021-07-01",{"name":320,"class":38},"Woman's"]